The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | AI-based insights into outcomes in pembrolizumab-treated NSCLC
Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, discusses two analyses of the Pembro-Real 5Y registry evaluating long-term survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab. One study focused on patients with poor performance status, showing that while overall prognosis remains poor, a subset achieves durable benefit, underscoring the limitations of standard predictors. The second study examined age-related outcomes, revealing that systemic health markers and functional status were more influential than chronological age in determining long-term survival. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
